Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

15-Year Follow-Up begins for myeloma cell therapy patients

NCT ID NCT03741127

Disease control Sponsor: Poseida Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 100 people with multiple myeloma who previously received an experimental cell therapy called P-BCMA-101. Researchers will monitor them for up to 15 years to see how safe and effective the treatment remains over time. A safety switch drug called rimiducid may also be given if needed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
P-BCMA-101 (a type of cell therapy) and rimiducid (a safety switch activator)
What this could lead to
If successful, this could show that P-BCMA-101 provides lasting control of multiple myeloma with manageable long-term side effects.
What could go wrong
This is an early-phase follow-up study, not a large trial. It may not prove long-term benefit, and risks like delayed side effects or loss of effectiveness remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2018

Expected to finish

Nov 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects who have received P-BCMA-101 and completed or discontinued early from a Poseida sponsored treatment protocol. * Subject has provided informed consent. Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • Colorado Blood Cancer Institute

    Denver, Colorado, 80218, United States

  • Johns Hopkins University

    Baltimore, Maryland, 21205, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Sarah Cannon Research Institute at Tennessee Oncology

    Nashville, Tennessee, 37203, United States

  • University of California Davis

    Davis, California, 95618, United States

  • University of California San Francisco

    San Francisco, California, 94143, United States

  • University of California, San Diego

    San Diego, California, 92121, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Kansas Cancer Center

    Westwood, Kansas, 66205, United States

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland, 21201, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37203, United States

  • Wayne State - Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.